论文部分内容阅读
目的探讨脑心通胶囊联合阿托伐他汀对脑梗死伴颈动脉粥样硬化患者的治疗效果。方法 68例脑梗死伴颈动脉粥样硬化患者作为研究对象,将患者随机分为常规组和联合组,每组34例。常规组患者给予阿托伐他汀及阿司匹林治疗,联合组患者在常规组基础上给予脑心通胶囊口服,将两组患者的治疗效果进行对比。结果治疗后,常规组总胆固醇(TC)为(3.1±0.8)mmol/L,甘油三酯(TG)为(1.2±0.3)mmol/L,高密度脂蛋白胆固醇(HDL-C)为(1.6±0.3)mmol/L,低密度脂蛋白胆固醇(LDL-C)为(2.2±0.3)mmol/L,联合组TC为(2.4±1.3)mmol/L,TG为(0.6±0.4)mmol/L,HDL-C为(1.9±0.2)mmol/L,LDL-C为(1.9±0.2)mmol/L,联合组患者的TC、TG、LDL-C水平明显低于常规组,HDL-C明显高于常规组,差异具有统计学意义(P<0.05)。治疗后,联合组患者颈动脉内-中膜厚度(IMT)为(1.0±0.2)mm、斑块面积为(0.5±0.2)cm~2,明显小于常规组的(1.3±0.2)mm、(0.7±0.2)cm~2,差异具有统计学意义(P<0.05)。结论脑心通胶囊联合阿托伐他汀能改善患者血脂,减少患者颈动脉粥样硬化,从而改善脑梗死预后,可在脑梗死伴颈动脉粥样硬化患者的治疗中推广。
Objective To investigate the therapeutic effect of Naoxintong capsule combined with atorvastatin on patients with cerebral infarction and carotid atherosclerosis. Methods Sixty-eight patients with cerebral infarction and carotid atherosclerosis were randomly divided into routine group and combined group, 34 cases in each group. Patients in the conventional group were treated with atorvastatin and aspirin. Patients in the combination group were given Naoxintong capsules orally on the basis of the conventional group, and the treatment effect was compared between the two groups. Results After treatment, the total cholesterol (TC) of the conventional group was (3.1 ± 0.8) mmol / L, the triglyceride (TG) was 1.2 ± 0.3 mmol / L and the HDL-C was ± 0.3 mmol / L LDL-C and (2.2 ± 0.3) mmol / L and (2.4 ± 1.3) mmol / L and (1.9 ± 0.2) mmol / L for HDL-C and (1.9 ± 0.2) mmol / L for LDL-C. The levels of TC, TG and LDL-C in the combined group were significantly lower than those in the conventional group In the conventional group, the difference was statistically significant (P <0.05). After treatment, carotid intima - media thickness (IMT) was (1.0 ± 0.2) mm and plaque area was (0.5 ± 0.2) cm ~ 2 in the combined group was significantly lower than that of the conventional group (1.3 ± 0.2) mm 0.7 ± 0.2) cm ~ 2, the difference was statistically significant (P <0.05). Conclusion Naoxintong capsules combined with atorvastatin can improve blood lipids in patients with reduced carotid atherosclerosis, thereby improving the prognosis of cerebral infarction, cerebral infarction patients with carotid atherosclerosis in the treatment of promotion.